Fenwick, Latham Lead Scribe Therapeutics' $129M IPO
By Jade Martinez-Pogue · July 24, 2026, 3:40 PM EDT
Early-stage biotechnology firm Scribe Therapeutics began trading publicly on Friday after raising $129 million in its upsized initial public offering steered by Fenwick & West LLP and Latham & Watkins LLP....
To view the full article, register now.